Background The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). Materials and methods We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Results Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter. Conclusion Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice. Prognostic factors are crucial to improve counseling of patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Our goal is to explore the role of Hemoglobin to RDW ratio in predicting progression-free survival and overall survival.
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations / Corianò, M., Lazzarin, A., Maffezzoli, M., Santoni, M., Mazzaschi, G., Rodella, S., Simoni, N., Lai, E., Maruzzo, M., Basso, U., Bimbatti, D., Iacovelli, R., Anghelone, A., Fiala, O., Rebuzzi, S.E., Fornarini, G., Lolli, C., Massari, F., Rosellini, M., Mollica, V., et al.. - In: IMMUNOTHERAPY. - ISSN 1750-743X. - (2025). [10.1080/1750743X.2025.2452145]
Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations
Lazzarin A.;Maffezzoli M.Formal Analysis
;Mazzaschi G.Methodology
;Simoni N.Writing – Review & Editing
;Acunzo A.;Silini E. M.Investigation
;Quaini F.Conceptualization
;De Filippo M.Writing – Review & Editing
;Buti S.Conceptualization
2025-01-01
Abstract
Background The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI). Materials and methods We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations. Results Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter. Conclusion Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice. Prognostic factors are crucial to improve counseling of patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations. Our goal is to explore the role of Hemoglobin to RDW ratio in predicting progression-free survival and overall survival.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
